Memorial Sloan-Kettering is the first and only hospital in New York, New Jersey, and Connecticut to offer a new, more patient-friendly approach for doctors to precisely pinpoint and remove small breast cancers.

In a large-scale genome-sequencing study, researchers have discovered mutations in neuroblastoma tumors that could aid the development of diagnostic tests and therapies.

Findings from a multidisciplinary research team led by Memorial Sloan-Kettering medical oncologist and immunologist Jedd Wolchok could help shed light on the immune system’s role in fighting cancer.

Memorial Sloan-Kettering investigators have developed a personalized tool to help women and their doctors predict overall survival at five years after a diagnosis of uterine leiomyosarcoma.

For the first time, a new study has shown that removing polyps by colonoscopy not only prevents colorectal cancer from developing, but also prevents deaths from the disease.

The director of the Spine Tumor Center explains how this new, high-powered approach to radiation therapy has changed the way spine tumors are treated at Memorial Sloan-Kettering.

The recent FDA approval of axitinib provides a viable treatment option for patients who progress on or cannot tolerate the side effects of other approved drugs for the disease.